Your browser doesn't support javascript.
loading
Haemophilus influenzae Protein D antibody suppression in a multi-component vaccine formulation.
Michel, Lea V; Kaur, Ravinder; Gleghorn, Michael L; Holmquist, Melody; Pryharski, Karin; Perdue, Janai; Jones, Seth P; Jackson, Niaya; Pilo, Isabelle; Kasper, Anna; Labbe, Natalie; Pichichero, Michael.
Afiliação
  • Michel LV; School of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
  • Kaur R; Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, NY, USA.
  • Gleghorn ML; School of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
  • Holmquist M; National Technical Institute for the Deaf, Rochester Institute of Technology, NY, USA.
  • Pryharski K; Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, NY, USA.
  • Perdue J; School of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
  • Jones SP; School of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
  • Jackson N; School of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
  • Pilo I; School of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
  • Kasper A; School of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
  • Labbe N; School of Chemistry and Materials Science, Rochester Institute of Technology, NY, USA.
  • Pichichero M; Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, NY, USA.
FEBS Open Bio ; 12(12): 2191-2202, 2022 12.
Article em En | MEDLINE | ID: mdl-36263849
ABSTRACT
Nontypeable Haemophilus influenzae (NTHi) has emerged as a dominant mucosal pathogen causing acute otitis media (AOM) in children, acute sinusitis in children and adults, and acute exacerbations of chronic bronchitis in adults. Consequently, there is an urgent need to develop a vaccine to protect against NTHi infection. A multi-component vaccine will be desirable to avoid emergence of strains expressing modified proteins allowing vaccine escape. Protein D (PD), outer membrane protein (OMP) 26, and Protein 6 (P6) are leading protein vaccine candidates against NTHi. In pre-clinical research using mouse models, we found that recombinantly expressed PD, OMP26, and P6 induce robust antibody responses after vaccination as individual vaccines, but when PD and OMP26 were combined into a single vaccine formulation, PD antibody levels were significantly lower. We postulated that PD and OMP26 physiochemically interacted to mask PD antigenic epitopes resulting in the observed effect on antibody response. However, column chromatography and mass spectrometry analysis did not support our hypothesis. We postulated that the effect might be in vivo through the mechanism of protein vaccine immunologic antigenic competition. We found when PD and OMP26 were injected into the same leg or separate legs of mice, so that antigens were immunologically processed at the same or different regional lymph nodes, respectively, antibody levels to PD were significantly lower with same leg vaccination. Different leg vaccination produced PD antibody levels quantitatively similar to vaccination with PD alone. We conclude that mixing PD and OMP26 into a single vaccine formulation requires further formulation studies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Anti-Haemophilus Limite: Animals Idioma: En Revista: FEBS Open Bio Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Anti-Haemophilus Limite: Animals Idioma: En Revista: FEBS Open Bio Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos